---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Prevalence"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Prevalence. Topics: Diagnosed prevalence by Shoulson-Fahn stage: share in stages 1 and 2; Sponsor statement: people with Huntington's disease in the United States, European Union, and United Kingdom; Sponsor estimate of the U.S. population treatable at launch; Sponsor risk disclosure: addressable population may be smaller than projected; 7 further topics. 11 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/prevalence"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Huntington's disease

<a id="topic-2.2.1.2.2-1"></a>

### Diagnosed prevalence by Shoulson-Fahn stage: share in stages 1 and 2

> “The model estimates that in 2020, there were 66,787 individuals diagnosed with HD in the 8 included countries, of whom 62-63% were in Shoulson-Fahn stages 1 and 2 (with less severely limited functional capacity than those in stages 3-5).”
> “Data on staging distribution at diagnosis, progression, and mortality were derived from Enroll-HD.”

Source: [Crowell et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34350853/)

<a id="topic-2.2.1.2.2-2"></a>

### Sponsor statement: people with Huntington's disease in the United States, European Union, and United Kingdom

> “Approximately 75,000 people have Huntington’s disease in the U.S., European Union (“EU”), and United Kingdom (“UK”), with approximately 40,000 symptomatic Huntington’s disease patients in the U.S.”
> “In addition to this, there are hundreds of thousands of others at risk of inheriting the disease.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.2.1.2.2-3"></a>

### Sponsor estimate of the U.S. population treatable at launch

> “Large anticipated total addressable US market at time of launch, with potential for further growth”
> “Sources: Fisher et al. 2014, Yohrling et al. 2020, *Management Estimate.”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

| U.S. population segment | Sponsor estimate |
| --- | --- |
| Initial treatable patients at launch (management estimate) | “~6,000” |
| Diagnosed HD | “~20,000 patients” |
| Symptomatic HD | “~40,000 patients” |
| Genetically identifiable HD | “~100,000 patients” |

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-2.2.1.2.2-4"></a>

### Sponsor risk disclosure: addressable population may be smaller than projected

> “The affected populations for our gene therapies may be smaller than we or third parties currently project, which may affect the size of our addressable markets.”
> “The total addressable market opportunities for these therapies will depend upon many factors, including the diagnosis and treatment criteria included in the final label, if approved for sale in specified indications, acceptance by the medical community, patient consent, patient access and product pricing and reimbursement, among other factors.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.2.1.2.2-5"></a>

### Global prevalence: updated systematic review and meta-analysis

> “Pooled prevalence was 4.88 per 100,000 (95% CI, 3.38-7.06). Subanalyses by continent demonstrated that the prevalence of HD was significantly higher in Europe and North America than in Africa.”

Source: [Medina et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10086981/)

<a id="topic-2.2.1.2.2-6"></a>

### Global prevalence: systematic review and meta-analysis, by region

> “The worldwide service-based prevalence of HD, based on a meta-analysis (n = 13 studies), was 2.71 per 100,000 (95% CI: 1.55-4.72). Eleven studies were conducted in Europe, North American, and Australia, with an overall prevalence of 5.70 per 100,000 (95% CI: 4.42-7.35). Three studies were conducted in Asia, with an overall prevalence of 0.40 per 100,000 (95% CI: 0.26-0.61).”

Source: [Pringsheim et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22692795/)

<a id="topic-2.2.1.2.2-7"></a>

### Geographic variation and prevalence trends

> “The prevalence of HD varies more than tenfold between different geographical regions.”
> “There was evidence of an increasing prevalence of between 15 and 20% per decade in studies from Australia, North America and Western Europe.”

Source: [Rawlins et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26824438/)

> “In populations of European ancestry, HD occurs at an average prevalence of 9.71:100,000 [Rawlins et al 2016], with up to 17:100,000 when multiple sources of ascertainment are accounted”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.2.2-8"></a>

### United States: symptomatic and at-risk population

> “Today, there are approximately 41,000 symptomatic Americans and more than 200,000 at-risk of inheriting the disease.”

Source: [Huntington's Disease Society of America (2020)](https://hdsa.org/what-is-hd/overview-of-huntingtons-disease/)

> “as many as ~40,000 people may have manifest HD in the US.”
> “Sources frequently state that 30,000 individuals living in the US have HD, but the methodology used to derive this prevalence estimate is unclear.”

Source: [Yohrling et al. (2019)](https://medically.gene.com/content/dam/pdmahub/restricted/neurology/hsg-2019/HSG-2019-poster-yohrling-prevalence-of-huntington-s-disease-in-the-US.pdf)

<a id="topic-2.2.1.2.2-9"></a>

### United States: claims-based prevalence

> “In the Medicare population, 1,941 prevalent and 819 incident cases of HD were identified in 2017, corresponding to a prevalence proportion of 13.1 per 100,000 persons and incidence rate of 6.1 per 100,000 person-years. In the Medicaid population, 353 prevalent cases of HD were identified in 2014, corresponding to a prevalence proportion of 15.2 per 100,000 persons.”

Source: [Exuzides et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/35483335/)

> “We estimated a cumulative age-adjusted HD frequency rate of 6.52 per 100,000 persons”

Source: [Bruzelius et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6579693/)

<a id="topic-2.2.1.2.2-10"></a>

### United Kingdom: primary care prevalence

> “The estimated prevalence (expressed per 100 000 population) rose from 5.4 (95% CI 3.8 to 7.5) in 1990 to 12.3 (95% CI 11.2 to 13.5) in 2010.”

Source: [Evans et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3786631/)

> “Annual prevalence steadily increased throughout the study period, with prevalence estimates ranging from 4.3 cases (3.6–5.1) per 100,000 in 2000 to 9.2 cases (8.1–10.5) per 100,000 people in 2018 (β = 0.27, p < 0.001).”

Source: [Furby et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542098/)

<a id="topic-2.2.1.2.2-11"></a>

### Juvenile and pediatric Huntington's disease: proportion in Enroll-HD

> “50 compared with 7544 adult (0.66%) and 22 out of 16,124 family participants (0.14%) were pediatric.”

Source: [Achenbach and Saft (2021)](https://pubmed.ncbi.nlm.nih.gov/34049236/)

Additional sources: [Yohrling et al. (2020)](https://www.neurology.org/doi/10.1212/WNL.94.15_supplement.954)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
